Tuesday - July 28, 2026
Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency
May 07, 2026
NEW YORK, May 7 [Category: BizFinancial Services] -- Blackstone, an investment firm, posted the following news release:

* * *

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency

People with exocrine pancreatic insufficiency currently face highly disruptive pill burden - ANG003 expected to only require one tablet per meal

NEW YOR . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products